Qiagen N.V.

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
41.65 ^USD	+1.39%		+4.12%	-6.98%

Apr. 24	QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use	CI
Apr. 22	European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	MT

QIAGEN NV : Independant Research reiterates its Neutral rating

August 26, 2019 at 07:37 am EDT

In a research note, Independant Research analyst Tobias Gottschalt has maintained his recommendation on the stock with a Neutral rating. The target price is unchanged and still at EUR 35.

Latest news about Qiagen N.V.

QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use	Apr. 24	CI
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
QIAGEN NV : Deutsche Bank reiterates its Buy rating	Apr. 16	ZD
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024	Apr. 03	CI
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland	Mar. 27	CI
QIAGEN Introduces QIAstat-Dx Analyzer 2.0 with Remote Test Results Access, Enhancing Collaboration Across Healthcare System	Mar. 25	CI
Qiagen Teams Up With Physicians Association for Tuberculosis Screening Program	Mar. 18	MT
Transcript : Qiagen N.V. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM	Mar. 05
QIAGEN NV : UBS reaffirms its Neutral rating	Mar. 01	ZD
Morgan Stanley Upgrades Qiagen to Overweight From Equalweight, Adjusts Price Target to $49.48 From $51	Feb. 16	MT
QIAGEN NV : Berenberg reiterates its Buy rating	Feb. 16	ZD
QIAGEN NV : Deutsche Bank remains its Buy rating	Feb. 14	ZD
Volta Labs Partners with OEM by QIAGEN to Unlock Potential of NGS Sample Prep	Feb. 08	CI
QIAGEN NV : JP Morgan reiterates its Buy rating	Feb. 08	ZD
QIAGEN NV : UBS reiterates its Neutral rating	Feb. 08	ZD
QIAGEN : In line Q4; routine business prospects remain intact	Feb. 07
Dpa-AFX Overview: COMPANIES from 07.02.2024 - 15:15	Feb. 07	DP
Sector Update: Health Care Stocks Mixed Premarket Wednesday	Feb. 07	MT
Transcript : Qiagen N.V., Q4 2023 Earnings Call, Feb 07, 2024	Feb. 07
QIAGEN NV : Gets a Neutral rating from UBS	Feb. 07	ZD
QIAGEN NV : Berenberg reaffirms its Buy rating	Feb. 07	ZD
QIAGEN NV : DZ Bank gives a Buy rating	Feb. 07	ZD
QIAGEN NV : Deutsche Bank reiterates its Buy rating	Feb. 07	ZD
Qiagen Q4 Adjusted Earnings, Sales Rise; 2024 Outlook Issued, Shares Slump	Feb. 06	MT
Qiagen N.V. Provides Earnings Guidance for Year 2024	Feb. 06	CI

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

QIAGEN : In line Q4; routine business prospects remain intact

February 07, 2024 at 10:30 am EST

More Strategies

Ratings for Qiagen N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

41.65 USD

Average target price

50.75 USD

Spread / Average Target

+21.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QIAGEN N.V.	-6.98%	9.09B
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research

Qiagen N.V.

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

QIAGEN NV : Independant Research reiterates its Neutral rating

Latest news about Qiagen N.V.

Chart Qiagen N.V.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Qiagen N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research